Allergic Rhinoconjunctivitis in the Australian Population: Burden of Disease and Attitudes to Intranasal Corticosteroid Treatment

Katelaris, Constance H.; Sacks, Raymond; Theron, Paul N

doi:10.2500/ajra.2013.27.3965

Cited by 19 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asia-Pacific data show that the most common reasons for patients to be dissatisfied with treatment for allergic rhinitis are inadequate efficacy and bothersome side effects [ 21 ]. Moreover, these are also reasons cited for nonadherence, along with symptom relief that does not last 24 hours and safety concerns with intranasal corticosteroids [ 65 ]. Poor adherence or inadequate treatment efficacy may explain why, in the Asia-Pacific allergies survey, only 42% of patients with allergic rhinitis reported that their symptoms were completely or well controlled [ 33 ].…”

Section: Unmet Needs In Allergy Management In Asia-pacificmentioning

confidence: 99%

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement

Mösges

Lee

Abong

et al. 2016

Asia Pacific Allergy

View full text Add to dashboard Cite

The prevalence of allergic diseases is increasing globally, most particularly in middle- to low-income countries. This article examines the burden of allergic rhinitis and chronic urticaria in the Asia-Pacific region, unmet clinical needs, and the potential role of bilastine in the management of these conditions. An International Advisory Group meeting was convened in association with the Asian Pacific Society of Respirology Annual Congress in November 2014, followed by a literature review, and consensus-based outcomes from the meeting and literature review are described. Regional estimates of the prevalence of allergic rhinitis range from 10% to 50%, while little is known regarding the burden of urticaria in the Asia-Pacific region. A survey of allergy patients in the region identified fast, complete, and long-lasting symptom relief as the medication attributes most important to patients. International treatment guidelines for allergic rhinitis and urticaria advocate the first-line use of second-generation, no-sedating H1-antihistamines, such as bilastine, over their first-generation counterparts and a range of these agents are available to Asia-Pacific patients. The newer agents possess many of the properties of an "ideal" antihistamine (once daily administration, rapid and complete symptom relief, limited potential for drug-drug interactions, minimal side effects). The burgeoning prevalence of allergic diseases in the Asia-Pacific region and the uncontrolled symptoms that these patients experience demand a new antihistamine that offers the highest number of positive features according to the international guidelines.

show abstract

Section: Unmet Needs In Allergy Management In Asia-pacificmentioning

confidence: 99%

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement

Mösges

Lee

Abong

et al. 2016

Asia Pacific Allergy

View full text Add to dashboard Cite

show abstract

“…Allergic rhinoconjunctivitis affects up to 40% of children and adolescents in westernized countries . This disease is commonly undiagnosed and underappreciated despite its significant impact on patients' quality of life and its overall economic burden . Direct costs caused by AR during 2004 for the US surpassed $6 billion/year .…”

Section: Introductionmentioning

confidence: 99%

The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis

Pizzulli

Perna

Florack

et al. 2014

Clin Experimental Allergy

View full text Add to dashboard Cite

DISSERTATION Original AbstractThe impact of tele-monitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitisBackground -Adherence to controller therapy in allergic diseases is low. Tele-monitoring has been proposed to improve adherence to treatment in chronic diseases. However, this strategy has never been tested in allergic rhinoconjunctivitis. Objective -To test whether Internet-based tele-monitoring during the grass pollen season of children with allergic rhinoconjunctivitis may enhance adherence to treatment. Methods -Children and adolescents, 5-18 years old, with moderate-to-severe seasonal allergic rhinoconjunctivitis to grass pollen requiring daily administration of nasal corticosteroid (mometasone) were recruited (April 2013) in a pediatric allergy practice. Participants were randomized to Internet-based monitoring (AllergyMonitor™, AM) or to usual care (no diary at all, controls) and followed from May 13th (T0) to June 15th 2013 (T2). An intermediate visit (T1) was performed between May 31st and June 2nd. Optimal adherence to therapy was expressed as the use of at least 0.190 g/day of mometasone, corresponding to one puff/nostril/day, and it was measured by canister weights during (T1) and at the end (T2) of the study period. Main secondary outcomes included the reported disease severity (validated self-questionnaire) and quality of life (AdoIRQLQ questionnaire), disease knowledge (multiple-choice questionnaire), nasal flow and resistance at baseline and at T2. Results -The use of mometasone, expressed as both optimal adherence rate (48.4% vs 12.5%; p=0.002) and average daily use (0.20+0.12 g/day vs 0.15+0.07 g/day; p=0.037), was higher in the AM group (n=31) than among controls (n=32). Disease knowledge improved among the patients using AM (83.3% vs 68.3%; p<0.001) but not among controls (68.2% vs 67.7% right answers; p>0.05). No differences were observed in the reported severity of disease, nasal flow and resistance and quality of life both at baseline and at follow-up visits. Conclusions -Internet-based tele-monitoring improves adherence to nasal corticosteroid treatment and disease knowledge among children and adolescents with seasonal allergic rhinoconjunctivitis.

show abstract

“…Our study revealed that patients overall purchased OTC OAHs (70.1% of rhinitis only patients and 57.3% of rhinitis and asthma/COPD patients) and that first-line INS therapy was more likely to be purchased for rhinitis and asthma/COPD patients (15.3% by prescription and 11.7% OTC) than for rhinitis only patients (5.0% by prescription and 9.2% OTC). Many studies have shown that most single therapy is purchased OTC than by prescription, and most often OAHs are purchased, 14 , 25 , 28 , 34 – 37 which are not clinically effective or cost-effective. 3 , 5 , 18 Our results are consistent with those from a recent community pharmacy-based study in Australia, where the majority of AR patients who had visited the pharmacy self-selected their medications, most of which were OTC OAHs, and 71% of OTC purchases of OAHs were self-selected by patients without seeking pharmacist advice.…”

Section: Discussionmentioning

confidence: 99%

Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease

Price

Smith

Harvey

et al. 2018

POR

View full text Add to dashboard Cite

BackgroundThe aim of the study was to explore rhinitis therapy purchases in different Australian regions for patients with and without additional respiratory disease, using both doctor’s prescriptions and over-the-counter (OTC) medications.Patients and methodsIt was a historical cohort study of pharmacy-related claims that included prescription or OTC rhinitis therapy, with or without asthma/COPD therapy, from January 2013 to December 2014.ResultsOverall, 4,247,193 prescription and OTC rhinitis treatments were purchased from 909 pharmacies over a calendar year; the majority were single-therapy purchases for rhinitis only patients. More multiple-therapy was purchased for rhinitis and asthma/COPD patients (4.4%) than for rhinitis only patients (4.0%), with a greater proportion purchased in VIC, SA and TAS (4.7% of rhinitis only patients and 4.5% of rhinitis and asthma/COPD patients) than in other areas. Dual therapy of oral antihistamine (OAH) and intranasal corticosteroid (INS) were the most frequently purchased multiple-therapy, with higher purchasing rates for rhinitis and asthma/COPD patients (2.6%) than for rhinitis only patients (1.6%). The most frequently purchased single therapy was OAH (70.1% of rhinitis only patients and 57.3% of rhinitis and asthma/COPD patients). First-line INS therapy was more likely to be purchased for rhinitis and asthma/COPD patients (15.3% by prescription and 11.7% OTC) than for rhinitis only patients (5.0% by prescription and 9.2% OTC); however, geographical differences in the proportion of therapies purchased OTC were noted, with a lower proportion of OTC OAH and INS purchases in Queensland and the Northern Territory for patients with and without comorbid respiratory disease.ConclusionPurchases of first-line INS therapy are more likely for patients with comorbid respiratory disease if they have received prescriptions and information/advice from their general practitioner. The study results indicate a need for patient information/education at the point-of-sale of OTC OAHs to enable patients to assess their nasal symptoms and receive treatment support from pharmacists. Greater availability to INSs in pharmacies as well as guidance from current guidelines and instruction in correct intranasal technique may also lead to greater uptake of INSs.

show abstract

Allergic Rhinoconjunctivitis in the Australian Population: Burden of Disease and Attitudes to Intranasal Corticosteroid Treatment

Abstract: ABSTRACT

Cited by 19 publications

References 24 publications

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement

Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement

The impact of telemonitoring on adherence to nasal corticosteroid treatment in children with seasonal allergic rhinoconjunctivitis

Real-life treatment of rhinitis in Australia: a historical cohort study of prescription and over-the-counter therapies for patients with and without additional respiratory disease

Contact Info

Product

Resources

About